Argatroban is a peptidomimetic synthetic direct thrombin inhibitor with reversible and specific properties resulting in predictable anticoagulant effects. Usually, argatroban therapy is monitored by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT). While other global clotting tests for the monitoring of anticoagulants are useful, their applicability to antithrombin agents (particularly of argatroban at higher dosages) is rather questionable. In this study, we sought to compare the argatroban anticoagulant levels in patients undergoing percutaneous transluminal angioplasty (PTCA) and stenting procedures, utilizing both functional and absolute quantitation methods. Argatroban produced a comparable increase of ACT and HMT, 5 to 10 minutes after administration. The level of anticoagulation achieved (400-450 seconds with ACT and HMT) following a slow bolus of argatroban (350 aglkg) was maintained throughout the procedure using 25 jtg/kg/min infusion. Following discontinuation of argatroban at the end of the procedure,
Heparin has been conventionally used as an anticoagulant for various medical and surgical indications, but increasing incidence of heparininduced thrombocytopenia (HIT) and HIT with thrombosis syndrome (HITTS), also known as white clot syndrome, necessitate the use of an anticoagulant drug as an alternate to heparin in such conditions. The HIT syndrome occurs in approximately 1% to 5% of the patients receiving heparin for at least 5 days (1, 2) . Unless diagnosed early and treated promptly, it would have serious thrombotic sequelae. The type II or the immune-mediated HIT/HITTS may occur in only the ACTs and HMTs showed a comparable progressive reduction in the anticoagulant response, which reflected the elimination of argatroban 2 to 3 hours after the procedure. No significant differences between the three methods (Hemotec, Hemochron, and HMT) were noted at any given sampling time. Argatroban dosage at 350 Ag/kg intravenous slow bolus followed by 25 Ag/kg/min infusion was adequate to perform PTCA and stenting procedures. There was no incidence of bleeding complications. Absolute quantitation of argatroban levels in patient plasmas by a newly developed HPLC method was found to be quite comparable with the ecarin clotting time (ECT) results. The ECT system was found to be less sensitive when compared to other tests, and therefore, could be used as a point-of-care test during the PTCA/stenting procedures to monitor argatroban. Key Words: Argatroban-Angioplasty-Anticoagulation tests-HPLC-Drug monitoring-Heparin-induced thrombocytopenia/ thrombosis. a few hours after heparin administration in patients who received heparin earlier within the previous 3 months (1, 2) . In known cases of HIT or HITTS that require percutaneous transluminal coronary angioplasty (PTCA) or stenting procedures, changing the brand of heparin (or lowmolecular-weight heparin) will not help and is not a safe alternate option (3, 4) .
Thrombin inhibitors such as argatroban, rhirudin, and PEG-hirudin, are currently undergoing extensive clinical trials in PTCA, acute myocardial infarction (AMI), percutaneous interventions (PCI), and for the treatment of unstable angina (5) (6) (7) . Argatroban (Novastan, Texas Biotechnology Corp, Houston; GlaxoSmithKline, Philadelphia), a synthetic, direct thrombin inhibitor, is in extensive clinical development as a substitute for heparin (8) (9) (10) . It directly blocks the catalytic site on thrombin (8, 11, 12) . It is an arginine derivative (molecular weight, 526.6 Da) with two large hy-drophobic side chains and inhibits both clot-bound and fibrin-bound thrombin (10, 13) .
Argatroban has recently been approved by the US Food and Drug Administration as an anticoagulant for prophylaxis or treatment of thrombosis in patients with HIT/HITTIS. In Japan, this agent is used in peripheral arterial occlusive disease and in acute ischemic stroke for a number of years (14) . Recently, we reported on the successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with HIT/HITTS (15) .
Due to the advances in biotechnology and organic synthetic chemistry, several other synthetic peptides and recombinant proteins have emerged. A dry chemistry technology developed by Cardiovascular Diagnostics, Inc (CDI; Raleigh, NC), based on the principle of the motion of paramagnetic iron oxide particles (PIOP), provides a rapid point-of-care test (heparin management test; HMT) to monitor the anticoagulant effects of thrombin inhibitors. Other methods, such as Hemotec and Hemochron celite ACT (activated clotting time) systems, and ECT (ecarin clotting time) (16, 17) , could also be used. Thus, a comparative validation of these methods to monitor the anticoagulant response of thrombin inhibitors, particularly argatroban, is essential. Therefore, this study compared the argatroban anticoagulant levels in patients undergoing PTCA and stenting procedures (ARG310 study), utilizing both functional and absolute quantitation methods.
MATERIALS AND METHODS
The thrombolytic assessment system (TAS) analyzer, HMT cards, and ECT cards, were obtained from CDI (Raleigh, NC). The Hemotec ACT machine and Hemotec cartridges (HR-ACT) were purchased from Medtronic HemoTec, Inc (Englewood, CO). The Hemochron ACT machine and the celite-ACT tubes were purchased from International Technidyne Corp (Edison, NJ). ACL 300 Plus and Automated Coagulation Analyzer were procured from Coulter Corp (Hileah, AZ). Argatroban vials (0.5 mg) were obtained from Texas Biotechnology Corp (Houston, TX). The ecarin reagent (Lot no. 8303/116-08) was obtained from Pentapharm AG (Basel, Switzerland).
Study Subjects and Design
Patients diagnosed to have clinical HIT syndrome combined with positive laboratory tests and who were required to undergo PTCA/stenting procedures were admitted at the Columbus Hospital, Chicago, and at the Loyola University Medical Center, Maywood, IL, under an approved Institutional Review Board (IRB) protocol (ARG310 study). Appropriate consent was obtained from each patient before participation in the study. Patients (n = 14) were administered argatroban before the PTCA procedure at a dosage of 350 ,Ag/kg slow bolus followed by 25 ,ug/kg/min infusion throughout the procedure. Citrated blood samples were drawn at baseline, 5 to 10 minutes post-bolus, during infusion, at the end of the procedure, 1 to 2 hours after the procedure, and 2 to 3 hours after the procedure. The blood samples were immediately processed to measure HMT, HemoTec, and Hemochron celite-ACT assays. Some of the citrated blood samples were then centrifuged at 3,000 rpm to obtain platelet-poor plasma (PPP). The plasma was aliquoted and frozen at -70°C until further use for additional analyses. The frozen samples were later thawed and batch-analyzed for argatroban levels using the ECT and high performance liquid chromatography (HPLC) methods.
The Dry Chemistry Technology
The TAS analyzer is a portable device designed for point-of-care monitoring and uses premade test cards to detect the formation of a clot in citrated plasma or citrated whole blood samples.
The individually packed disposable HMT test cards are the size of a regular credit card with a magnetic stripe at the back which is encoded with test type, expiration date and other quality assurance information. The test card has a reaction chamber, which contains dry reagents and PIOP. The test principle is based on sensing the oscillations of PIOP after the blood or plasma sample is added to the reaction chamber in the presence of a fluctuating magnetic field. Clot formation results in cessation of particle movement. The analyzer detects movement of particles and records the clotting time due to antithrombin agent. Individual patient's results can be stored and retrieved through the LCD display. The TAS analyzer is in accordance with the Clinical Laboratories Improvement Amendments (CLIA). Similarly, the HMT cards, and the ECT cards also work on the above principle.
Ecarin Clotting Time
The ECT is a specific test to monitor antithrombin drugs such as argatroban (16) (17) (18) . Ecarin is a single-chain glycoprotein (molecular weight, 55-60 kDa) extracted from the snake (Echis carinatus) venom. It catalyzes the hydrolytic cleavage of 323Arg-324 Ile bond in the human prothrombin molecule and forms an intermediate called meizothrombin. Meizothrombin is inhibited by thrombin inhibitors such as argatroban; however, it is not inhibited by heparin-antithrombin III (AT) complex. Meizothrombin is autocatalytically converted into ctthrombin and the a-thrombin is then inhibited by heparin-AT complex. Based on this original ECT technology (18) , ecarin reagent was placed in the dry chemistry test cards (CDI; Raleigh, NC), to develop the ECT test cards. To monitor the antithrombin drug levels at higher concentrations in biological fluids, the ecarin reagent along with celite was placed in the card system to develop the celite-ECT cards (CDI; Raleigh, NC). Calibration curves were constructed after supplementing argatroban in whole blood and/or PPP, and such tests as the celite-ACT, HMT, ECT, celite-ECT, and HPLC, were performed.
HPLC Instrumentations and Procedures
The HPLC method used in this study for the absolute quantitation of argatroban and its major Ml-metabolite has been described recently (19) . Briefly, to extract argatroban, 70,L plasma samples were diluted 5-fold with normal saline (Baxter Healthcare Corporation, Deerfield, IL), and deproteinized with 0.7 mL of acetonitrile (Sigma Chemical Company, St. Louis) in microcentrifuge tubes, and then vortexed for at least 30 seconds. The protein sedimentation was performed by centrifugation at 10,000 rpm for 15 minutes. , and recentrifuged at 10,000 rpm for 15 minutes, which yielded supernatants of consistent quality. A 50-AL sample was transferred to insert assembled target vials and placed in the autosampler processor of the HPLC system.
The system used was a Waters 845 HPLC-GPC System (Milford, MA) equipped with a tunable ultraviolet detector set at 333 nm or 320 nm (as required), and a computer with printer. A 50-,utL aliquot of each sample (isolated above) was injected onto a C-18 reverse phase HPLC column (no. OOF-3125-EO; Phenomenex, Torrance, CA) with a guard column (no. 03A-3125-EO; Phenomenex), using mobile phase with a flow rate of 1.0 mL/min. The run time for each chromatogram was 15 minutes. Calibration curves were prepared every time by running known standard of argatroban and/or Ml supplemented in normal human plasma, NHP (20 ,ug/mL serially diluted down to 0 ,ug/mL) and mixtures of Ml-metabolite and argatroban in NHP (each 20 ,tg/mL down to 0,g/mL). These calibration samples also underwent similar treatment of extraction procedure(s). The argatroban and/or Ml (if any) peak(s)' area under the curve (AUC) was determined according to the standard method of such calculations performed by computer analysis (19) .
Statistical Analyses
Data are expressed as mean + standard error of the mean using ANOVA. The argatroban levels in a given patient plasma sample expressed as micrograms per milliliter or its anticoagulant corresponding clotting time in seconds.
RESULTS
The results of the argatroban anticoagulant responses in the Hemotec ACT, Hemochron ACT and HMT card systems are shown in Figs. 1-3 , respectively. The baseline values of Hemotec ACT, Hemochron ACT, and HMT were found to be 133.6 ± 33.8, 147.5 ± 32.7, and 193.9 + 60.0 seconds, respectively. Following 5 to 10 minutes of argatroban administration at a dosage of 350 ,ug/kg IV bolus, these values increased to 412.7 ± 71.1, 420.2 ± 97.6, and 423.7 ± 50.0 seconds, respectively ( Figs. 1-3 ). Subsequently, during the infusion of argatroban at a dosage of 25 ,ug/kg/min, these values remained basically the same at 453.4 + 90.0, 419.2 ± 80.4, and 424.2 ± 50.3 seconds, respectively. There was no significant change in these readings at the end of the procedure (Figs. 1-3 Figs. 1-3) .
The argatroban pharmacodynamic response was measured by the ECT assay performed using the automated coagulation laboratory (ACL) method. Fig. 4 shows that a baseline value of 46.9 ± 2.32 seconds was noted, and following the argatroban administration, during the infusion, and till the end of the procedure, the ECT values were maintained around the maximum ECT measurable limit of 999 seconds (Fig. 4) . At 1 to 2 hours post-interval, the ECT values were in the range of 400 to 450 seconds, which decreased to less than 300 seconds at 2 to 3 hours, post time-point.
The used. In this system, from a baseline value of about 35 seconds, the celite-ECT increased to 700 seconds following the administration of argatroban bolus (Fig. 5 ). During the infusion and at the end of the procedure, the values increased from 600 to 900 seconds, and then declined to less than 200 seconds (Fig. 5 ). Because the celite-ECT assay was found to be less sensitive in monitoring argatroban levels, a calibration curve was made by supplementing argatroban in blood bank plasma (BBP) and determining the celite- were analyzed to determine the celite-ECT test, and the circulating levels of argatroban were calculated based on the calibration curve.
Because the clotting tests often results in erroneous results due to hemodilution, other anticoagulant contamination, and so on, we sought to make sure that the drug concentrations during the procedure (as measured by the above clotting tests) were mainly due to the argatroban dosing. To this end, we used a recently developed HPLC system where absolute levels of argatroban and its major Ml-metabolite can be quantitated simultaneously (19) . The results of the circulating levels of argatroban based on the HPLC measurements are shown in Fig. 6 . The data clearly show that during the argatroban anticoagulation, the HPLC results were comparable with the circulating levels determined by the celite-ECT card system. The circulating concentrations of argatroban following the argatroban administration of bolus, during infusion, and at the end of the procedure, were in the range of 3 to 7,g/mL and these values subsequently decreased to reach a value of around 2,ug/mL at 2 to 3 hours, post time-point (Fig. 6) . Interestingly, no significant levels of Ml-metabolite of argaroban could be detected (< 0.5 ,ug/mL of Ml at all time points), suggesting that no metabolic transformation of argatroban occurred during this type of acute argatrobarrtherap''y (although at a relatively higher dosage).
DISCUSSION
Argatroban is a synthetic antithrombin agent that targets the clotting process by inhibiting thrombin (10) , with a well-defined and distinct chemical structure. This agent appears to be able to produce anticoagulation comparable to heparin for therapeutic and interventional procedures (13, 20, 21) . In a recently completed clinical trial (ARG911 study) (15) , argatroban produced therapeutic anticoagulation at relatively lower levels (1-2,g/mL circulating drug concentrations) comparable to activated partial thromboplastin time (aPTT 70-100 seconds) in patients with HIT who required alternate anticoagulant therapy.
The purpose of this investigation was to study the efficacy of argatroban in patients undergoing PTCA/stent procedures. Monitoring and specific quantitation of argatroban is crucial in the management of patients undergoing such procedures as PTCA or stenting (22) (23) (24) . Conventional global clotting tests such as prothrombin time (PT), aPTT, or ACT are relatively less sensitive to measure the anticoagulant effects of argatroban. Furthermore, these tests are not specific for the determination of the absolute concentrations of argatroban. The dry chemistry test card technology based on the principle of oscillation of paramagnetic iron oxide particles provides a unique, sophisticated approach in the rapid point-of-care monitoring of the anticoagulant response. This study compared the results of HMT card utilizing the dry-chemistry technology concept with the conventionally used ACT measurements by Hemochron and Hemotech systems. Furthermore, the data are compared with the absolute measurements of argatroban and its major Ml-metabolite levels by analytical method such as HPLC.
The ECT test is highly specific for antithrombin drugs, including argatroban. It is not affected by the presence of other anticoagulants such as warfarin or heparin. ECT is also not affected by ATIII, tissue factor pathway inhibitor (TFPI), platelet factor 4 (PF4), or fibrinogen up to 50 mg/mL. The ecarin levels can also be adjusted to obtain desired levels of sensitivity. The circulating levels of antithrombin agents produce agentspecifc effects in various functional assays. Moreover, the relative degree of thrombin inhibition is not proportional to the anticoagulant or antithrombotic efficacy of various antithrombin agents. The aPTT and thrombin time (TT) assays show wide variations in different patient groups due to differences in plasma matrices. The circulating levels of antithrombin drugs can also be immunoquantitated by ELISA (antigen-based) and UPLC methods; however, these levels may or may not be relevant to the functional anticoagulant activity. ECT provides a useful method to determine circulating levels of antithrombin agents. ECT can be performed using the liquid reagent or the dry chemistry technology. When the ECT measurements reached the maximum detection limits, the use of a stronger ecarin reagent such as the celite-ecarin combination improved the assay sensitivity. While the aPTT assay is affected by high factor VIII and fibrinogen levels, the ECT system is not affected by these compounds. Similarly, the aPTT assay is affected by the thrombolytic agents, whereas the ECT assay is not affected by the thrombolytic agents. The ECT (ACL) method used in the PTCA trial although reached a sensitivity limit following the bolus administration of argatroban and continued to remain above sensitivity limits during the infusion and till the end of the procedure, the later decline in the circulating levels of argatroban were measurable. However, when the celite-ECT cards were used, the sensitivity level diminished and the argatroban activity was measurable even following the bolus administration of argatroban, and the pharmacodynamic response declined gradually at 2 to 3 hours following the procedure. Although the HMT card system could also be used in the monitoring of argatroban during PTCA procedure, the ECT tests are more specific in the monitoring of argatroban.
The results of the circulating concentrations using the ECT tests and the absolute quantitation of the circulating levels of the drug by HPLC method were found to be quite comparable. The circulating concentrations of argatroban following the bolus administration of 350 ag/kg followed by an infusion of 25 ,ug/kg/min were found to be in the range of 3 to 8 ,ukg/mL. Because there were no significant bleeding complications observed, we think that these circulating levels of argatroban are adequate to perform PTCA or stenting procedures and may generally be safe and efficacious in this kind of indication. Interestingly, compared to argatroban, no appreciable amounts of Ml-metabolite level was noted in these plasma samples suggesting that in the acute argatroban anticoagulation, no metabolic transformation occurs. Furthermore, recent studies suggest that argatroban does not mobilize PF4, and thus, do not generate antibodies that alter its anticoagulant activity in patients with HIT syndrome (25) .
Thus, we conclude that argatroban can safely be used in PTCA/stenting and related surgical/interventional procedures, where higher dosage of this agent is required. Furthermore, to monitor this agent, ECT cards can be utilized as a point-of-care test system. However, larger prospective studies are needed to further validate/strengthen these observations.
